Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of TRAIL-R2 (DR5) Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer

NCT02991196 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT02991196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02991196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of TRAIL-R2 (DR5) Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer
Lead sponsor
Daiichi Sankyo
Phase
Phase 1
Overall status
Terminated
Start date
December 1, 2016
Completion date
September 22, 2017
Enrollment
4 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasm